Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development and has multiple partnerships to gain access to disease targets and develop novel human antibodies. Genmab was founded in February 1999 and is publicly traded on the OMX Nordic Exchange Copenhagen A/S.

Genmab has assembled highly skilled and experienced pre-clinical and clinical teams and has established a streamlined process to coordinate product discovery, manufacturing, pre-clinical testing, clinical trial design, data management and regulatory submissions.

The company's operations are conducted internationally through the parent company Genmab A/S in Copenhagen, Denmark and the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab Ltd. in Hertfordshire, United Kingdom, Genmab, Inc. in Princeton, New Jersey, USA and Genmab MN, Inc. in Brooklyn Park, Minnesota, USA.

Articles of Association

Please click these links to read Genmab's Articles of Association:
Danish version
English version

General Guidelines for Incentive Programmes

Please click these links to read Genmab’s general guidelines adopted at the general meeting on 23 April 2008 pursuant to section 69(b) of the Danish companies act governing incentive programmes for the board of directors and the executive board of Genmab A/S:
Danish version